Liposarcoma of the left hemithorax and implications of MDM2

被引:1
|
作者
Stolten, Michael [1 ]
Sahasrabudhe, Deepak [1 ]
Constine, Louis [1 ]
机构
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
关键词
adjuvant radiation therapy; liposarcoma; MDM2; thorax; AMPLIFICATION; TUMORS;
D O I
10.1017/S1460396919000372
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Use of molecular information to guide clinical management of thoracic liposarcoma following resection. Case presentation: We present a case of a large liposarcoma of the left hemithorax. Initial biopsy consistent with lipoma however following resection pathology showed well-differentiated liposarcoma. Clinical data and molecular information including MDM2 from the tumour were employed in decision making regarding subsequent adjuvant radiation therapy versus close observation. Conclusion: Improved molecular characterisation has increased the precision of histological diagnoses and prediction of outcomes for many cancers. These may continue to help guide and strengthen clinical decision making and recommendations as they pertain to adjuvant therapy versus observation in the case of this patient.
引用
收藏
页码:397 / 399
页数:3
相关论文
共 50 条
  • [1] Primary liposarcoma of the uterus with MDM2 negative
    Wei, Shufei
    Zhang, Lushun
    Han, Yongliang
    Wang, Liangliang
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2024, 67 (04) : 907 - 910
  • [2] MDM2 inhibition in liposarcoma: a step in the right direction
    Constantinidou, Anastasia
    Pollack, Seth M.
    Jones, Robin L.
    LANCET ONCOLOGY, 2012, 13 (11): : 1070 - 1071
  • [3] The novel role of MDM2 in the diagnosis and treatment of dedifferentiated liposarcoma
    Ichikawa, Jiro
    Kawasaki, Tomonori
    Onohara, Kojiro
    Kanno, Satoshi
    Wako, Masanori
    Ochiai, Satoshi
    Aoki, Kaoru
    Haro, Hirotaka
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [4] Extracellular Vesicle MDM2 DNA: A Biomarker for Retroperitoneal Liposarcoma?
    Grignol, V.
    Casadei, L.
    Sarchet, P.
    de Faria, F. Costas Casal
    Pollock, R.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S38 - S38
  • [5] Relevance of FNCLCC Grade and MDM2 Amplification Levels in Dedifferentiated Liposarcoma
    Jour, G.
    Gullett, A.
    Liu, M.
    Hoch, B. L.
    MODERN PATHOLOGY, 2014, 27 : 19A - 19A
  • [6] Dedifferentiated melanoma with MDM2 gene amplification mimicking dedifferentiated liposarcoma
    Yousef, Samer
    Joy, Christopher
    Velaiutham, Shanta
    Maclean, Fiona M.
    Harraway, James
    Gill, Anthony J.
    Vargas, Ana Cristina
    PATHOLOGY, 2022, 54 (03) : 371 - 374
  • [7] Relevance of FNCLCC Grade and MDM2 Amplification Levels in Dedifferentiated Liposarcoma
    Jour, G.
    Gullet, A.
    Liu, M.
    Hoch, B. L.
    LABORATORY INVESTIGATION, 2014, 94 : 19A - 19A
  • [8] Analysis of MDM2 and TP53 genes in canine liposarcoma
    Muscatello, Luisa Vera
    de Biase, Dario
    Maloberti, Thais
    di Oto, Enrico
    Tallini, Giovanni
    Pellegrino, Valeria
    Bacci, Barbara
    Roccabianca, Paola
    Lepri, Elvio
    Crippa, Luca
    Avallone, Giancarlo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [9] Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma
    Bispo, Rosalvo Zosimo, Jr.
    de Camargo, Olavo Pires
    de Oliveira, Claudia Regina G. C. M.
    Filippi, Renee Zon
    Baptista, Andre Mathias
    Caiero, Marcelo Tadeu
    CLINICS, 2008, 63 (02) : 157 - 164
  • [10] MDM2 Copy Numbers in Well-Differentiated and Dedifferentiated Liposarcoma
    Ware, Patrick L.
    Snow, Anthony N.
    Gvalani, Maya
    Pettenati, Mark J.
    Qasem, Shadi A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (03) : 334 - 341